• news and publications | Enterprise Therapeutics | Treatment of respiratory diseases

PUBLICATIONS, NEWS & EVENTS

Enterprise Therapeutics doses first subjects in Phase 1 trial for First-in-Class cystic fibrosis therapy ETD002

ETD002 is a novel TMEM16A chloride channel potentiator
August 17, 2020/by admin

Enterprise Therapeutics appoints Dr David Morris MD as Chief Medical Officer

Dr Morris will lead Enterprise’s therapeutics development strategy…
February 10, 2020/by admin

Enterprise Therapeutics publishes paper on novel therapeutic approach for treatment of all cystic fibrosis patients

“TMEM16A Potentiation: A Novel Therapeutic Approach for…
January 8, 2020/by admin

TMEM16A Channel Function Does Not Influence Goblet Cell Numbers or Mucin Secretion In The Human Airway Epithelium – NACFC – Nashville – October 2019

TMEM16A Channel Function Does Not Influence Goblet Cell Numbers…
November 7, 2019/by admin

EACT Increases Intracellular Calcium Levels by a Tmem16a-Independent Mechanism – NACFC – Nashville – October 2019

EACT Increases Intracellular Calcium Levels by a Tmem16a-Independent…
November 7, 2019/by admin

The In Vitro & In Vivo Pharmacology of Novel Tmem16a Potentiator Compounds – NACFC – Nashville – October 2019

The In Vitro & In Vivo Pharmacology of Novel Tmem16a Potentiator…
November 7, 2019/by admin

Enterprise Therapeutics awarded up to £5.7M ($7M) from Cystic Fibrosis Foundation to Support Clinical Development of Novel Chloride Channel Modulator

Support for clinical development up to end of Phase 2 for…
October 15, 2019/by admin

ECFS Clinical Meeting Liverpool TMEM16A potentiator

ECFS Clinical Meeting Liverpool TMEM16A potentiator

Objectives:…
October 9, 2019/by admin

A systematic comparison of the profiles of inhaled ENaC blocker candidates on mucociliary clearance: are we under-dosing in clinical studies?

A systematic comparison of the profiles of inhaled ENaC blocker…
October 9, 2019/by admin

Something old and something new: ENaC & TMEM16A as targets to hydrate mucus in the CF airway

Something old and something new: ENaC & TMEM16A as targets…
October 9, 2019/by admin

The pharmacology of novel TMEM16A potentiator compounds

The pharmacology of novel TMEM16A potentiator compounds

Henry…
April 2, 2019/by admin

TMEM16A channel function does not influence goblet cell numbers in the human airway epithelium

TMEM16A channel function does not influence goblet cell numbers…
April 2, 2019/by admin

Enterprise is a biopharmaceutical company dedicated to the research and development of novel therapies for the treatment of respiratory diseases of high unmet medical need and commercial opportunity – the company plans to initiate clinical trials in 2020.

Scientific Strategy

Enterprise is developing muco-regulatory drugs that are expected to help respiratory patients by improving their ability to breath and reduce the number of lung infections they experience leading to a longer and more healthy life.

Learn more

Pipeline

Enterprise has developed a pipeline of novel low molecular weight compounds with first in class potential – our most advanced compounds, which target ion channels in the airway epithelium are expected to enter human trials in 2020.

Learn more